HEALTHPEAK PROPERTIES, INC.

Listed Company

DOCCIK 0000765880NYSELarge AcceleratedReal Estate Investment TrustsMarylandFY ends Dec 31

Period

FY 2025

Revenue

$2.82B

Net Income

$71.35M

Total Assets

$20.34B

Equity

$7.50B

Shares Out

695.04M

Op. Cash Flow

$1.25B

Business

Healthpeak Properties, Inc. owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States. It offers outpatient medical buildings, hospitals, lab buildings, continuing care retirement communities (CCRCs) structured through RIDEA arrangements, and related property management, financing and investment services. Its key business segments are outpatient medical, lab, and CCRC, with other non-reportable interests including a senior housing joint venture and loans receivable. Its properties are concentrated in U.S. healthcare and life-science markets—including hospital-adjacent sites and research hubs such as San Francisco, San Diego, and Boston—and are leased to healthcare delivery systems, life-science companies, and specialty operators.

Summary from filing dated 2025-02-04

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Rental and related revenues	2,157	2,087	1,632	1,542	1,378
Resident fees and services	604	568	527	495	471
Interest income and other	62	45	22	23	38
Total revenues	2,823	2,700	2,181	2,061	1,896
Operating	1,129	1,075	902	—	—
Depreciation and amortization	1,059	1,057	750	711	684
Interest expense	305	280	200	173	158
General and administrative	90	97	95	131	98
Transaction and merger-related costs	26	133	18	5	2
Impairments and loan loss reserves (recoveries), net	−893,000	23	−6	7	23
Total costs and expenses	2,608	2,665	1,959	1,889	1,739
Gain (loss) on sales of real estate, net	69	179	86	9	191
Other income (expense), net	479,000	59	7	326	6
Total other income (expense), net	70	238	93	335	−29
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	284	273	315	507	128
Income tax benefit (expense)	−9	−4	10	4	3
Equity income (loss) from unconsolidated joint ventures	−174	−2	10	2	6
Net income (loss)	101	267	335	516	526
Noncontrolling interests share in earnings	−30	−24	−29	−16	−18
Net income (loss) attributable to Healthpeak Properties, Inc.	71	243	306	500	506
Participating securities share in earnings	−834,000	−758,000	−2	−3	−3
Net income (loss) applicable to common shares	71	242	304	498	502
Basic (in dollars per share)	0.1	0.36	0.56	0.92	0.93
Diluted (in dollars per share)	0.1	0.36	0.56	0.92	0.93
Basic (in shares)	696	676	547	539	539
Diluted (in shares)	696	676	547	539	539

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-02-29	FY 2023 2023-12-31	FY 2022 2022-12-31
Buildings and improvements	16,594	16,115	—	13,329	12,784
Development costs and construction in progress	1,011	880	—	643	760
Land and improvements	3,007	2,919	—	2,648	2,667
Accumulated depreciation	−4,512	−4,083	—	−3,592	−3,188
Net real estate	16,099	15,831	—	13,028	13,023
Loans receivable, net of reserves of $11,345 and $10,499	606	656	—	218	375
Investments in unconsolidated joint ventures	803	937	—	783	707
Accounts receivable, net of allowance of $2,018 and $2,243	78	77	—	56	53
Cash and cash equivalents	467	120	—	118	72
Restricted cash	70	64	—	51	55
Intangible assets	655	817	—	314	418
Assets held for sale	81	8	—	118	50
Right-of-use asset	412	424	—	240	237
Deferred tax assets	111	115	—	—	—
Goodwill	69	69	51	—	—
Other assets	885	820	—	772	781
Total assets	20,336	19,938	—	15,699	15,771
Bank line of credit and commercial paper	1,079	150	—	—	—
Term loans	1,647	1,646	—	497	496
Senior unsecured notes	6,773	6,563	—	5,403	4,659
Mortgage debt	349	357	—	256	347
Intangible liabilities	174	192	—	127	156
Liabilities related to assets held for sale	12	0	—	729,000	4
Lease liability	296	307	—	207	209
Accounts payable, accrued liabilities, and other liabilities	719	725	—	657	772
Deferred revenue	985	940	—	906	844
Total liabilities	12,034	10,881	—	8,774	8,483
Commitments and contingencies (Note 12)	—	—	—	—	—
Redeemable noncontrolling interests	160	3	—	49	106
Common stock, $1.00 par value: 1,500,000,000 shares authorized; 695,036,731 and 699,485,139 shares issued and outstanding	695	699	—	547	547
Additional paid-in capital	12,768	12,847	—	10,406	10,350
Cumulative dividends in excess of earnings	−5,953	−5,174	—	−4,622	−4,270
Accumulated other comprehensive income (loss)	−10	29	—	19	28
Total stockholders equity	7,500	8,401	—	6,350	6,655
Joint venture partners	295	316	—	311	328
Non-managing member unitholders	347	338	—	215	200
Total noncontrolling interests	643	654	—	526	528
Total equity	8,143	9,055	—	6,876	7,183
Total liabilities and equity	20,336	19,938	—	15,699	15,771

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization of real estate, in-place lease, and other intangibles	1,059	1,057	750	711	684
Stock-based compensation amortization expense	14	16	14	26	18
Merger-related post-combination stock compensation expense	0	16	0	0	—
Amortization of deferred financing costs and debt discounts (premiums)	32	29	12	11	9
Straight-line rents	−39	−41	−14	−49	−31
Amortization of above (below) market lease intangibles	−37	−31	−26	—	—
Amortization of non-refundable entrance fees	−99	−89	−83	—	—
Equity loss (income) from unconsolidated joint ventures	174	2	−10	−2	−11
Distributions of earnings from unconsolidated joint ventures	17	12	910,000	943,000	5
Deferred income tax expense (benefit)	4	−2	−15	−6	−6
Impairments and loan loss reserves (recoveries), net	−893,000	23	−6	7	56
Loss (gain) on sales of real estate, net	−69	−179	−86	−10	−605
Loss (gain) upon change of control, net	0	−78	−234,000	−311	−1
Casualty-related loss (recoveries), net	621,000	29	−3	7	2
Other non-cash items	−10	−6	5	6	−8
Decrease (increase) in accounts receivable and other assets	−16	−41	−22	−17	19
Increase (decrease) in accounts payable, accrued liabilities, and other liabilities	−25	−29	−41	136	8
Increase (decrease) in deferred revenue	147	114	145	—	—
Net cash provided by (used in) operating activities	1,252	1,070	956	900	795
Acquisitions of real estate	−487	−7	−16	−178	−1,483
Development, redevelopment, and other major improvements of real estate	−764	−597	−731	−862	−611
Leasing costs, tenant improvements, and recurring capital expenditures	−134	−116	−114	−109	−111
Proceeds from sales of real estate, net	338	649	142	48	2,399
Proceeds from the Callan Ridge JV transaction, net	0	126	0	0	0
Investments in unconsolidated joint ventures	−87	−62	−88	−21	−25
Distributions in excess of earnings from unconsolidated joint ventures	29	23	21	13	38
Proceeds from insurance recovery	20	9	25	1	0
Proceeds from sales/principal repayments on loans receivable and other	148	93	205	116	342
Investments in loans receivable and other	−98	−52	−20	−11	−18
Cash paid in connection with the Merger, net	0	−179	0	0	—
Net cash provided by (used in) investing activities	−1,035	−114	−577	−876	531
Borrowings under bank line of credit and commercial paper	12,121	3,741	10,345	15,882	16,821
Repayments under bank line of credit and commercial paper	−11,192	−4,311	−10,620	−16,053	−15,785
Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt	987	750	744	500	1,089
Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt	−807	−27	−90	−5	−2,426
Payments for deferred financing costs	−3	−20	−7	−4	−237
Issuance of common stock, net of offering costs	1	317,000	278,000	308	5
Repurchase of common stock	−97	−191	−7	−68	−13
Dividends paid on common stock	−849	−795	−657	−648	−650
Distributions to and purchase of noncontrolling interests	−38	−90	−45	−31	−93
Contributions from and issuance of noncontrolling interests	13	12,000	489,000	1	640,000
Net cash provided by (used in) financing activities	136	−941	−337	−117	−1,289
Net increase (decrease) in cash, cash equivalents, and restricted cash	353	15	42	−93	38

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro